Cargando…

Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer

SIMPLE SUMMARY: Prostate cancer (PCa) is the second most common cancer in men and one of the leading causes of death. Signal transducers and activators of transcription (STATs) are transcription factors involved in the development and progression of several cancers, including PCa. STATs play a cruci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebersbach, Celina, Beier, Alicia-Marie K., Thomas, Christian, Erb, Holger H. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508518/ https://www.ncbi.nlm.nih.gov/pubmed/34638338 http://dx.doi.org/10.3390/cancers13194854

Ejemplares similares

Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue
por: Ebersbach, Celina, et al.
Publicado: (2022)

Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells
por: Sommer, Ulrich, et al.
Publicado: (2022)

Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue
por: Sommer, Ulrich, et al.
Publicado: (2022)

Metabolic changes during prostate cancer development and progression
por: Beier, Alicia-Marie K., et al.
Publicado: (2022)

A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment Response
por: Siciliano, Tiziana, et al.
Publicado: (2021)

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
por: Erb, Holger H. H., et al.
Publicado: (2020)

The Androgen Hormone-Induced Increase in Androgen Receptor Protein Expression Is Caused by the Autoinduction of the Androgen Receptor Translational Activity
por: Siciliano, Tiziana, et al.
Publicado: (2022)

Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines
por: Donix, Lukas, et al.
Publicado: (2022)

Impact of treatment on progression to castration‐resistance, metastases, and death in men with localized high‐grade prostate cancer
por: Miller, Eric T., et al.
Publicado: (2016)

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
por: Lobo-Martins, Soraia, et al.
Publicado: (2020)

Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients
por: León-Mateos, Luis, et al.
Publicado: (2020)

Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer
por: Røe, Kathrine, et al.
Publicado: (2013)

Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines
por: Linke, Dinah, et al.
Publicado: (2022)

The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer
por: Bishop, Jennifer L., et al.
Publicado: (2014)

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway
por: Luo, Yong, et al.
Publicado: (2021)

A rare case of isolated castrate resistant bilateral testicular metastases in advanced prostate cancer
por: Su, Jiarui, et al.
Publicado: (2018)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer
por: Mohanty, Sambit K., et al.
Publicado: (2017)

Lymphangitic Pulmonary Metastases in Castrate-Resistant Prostate Adenocarcinoma
por: Meyer, Andrew, et al.
Publicado: (2012)

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling
por: Nappo, G, et al.
Publicado: (2017)

Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
por: Wang, Keshan, et al.
Publicado: (2018)

Re: Maria J. Ribal, Philip Cornford, Alberto Briganti, et al. European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.056: Metastatic Prostate Cancer and COVID-19: Do Current Data Allow Modification of Established Treatment Recommendations?
por: Thomas, Christian, et al.
Publicado: (2020)

Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases
por: Polavaram, Navatha Shree, et al.
Publicado: (2021)

Proteomic Characterization of Prostate Cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases
por: Müller, Ann-Kathrin, et al.
Publicado: (2017)

Dural Metastases of Advanced Prostate Cancer Detected by (18)F-Fluorocholine
por: Morassi, Mauro, et al.
Publicado: (2020)

An unusual complication of prostatic bony metastases
por: Barnard, S. A., et al.
Publicado: (2015)

Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?
por: Thomas, Christian, et al.
Publicado: (2021)

Tumor- and Osteoblast-Derived Periostin in Prostate Cancer bone Metastases
por: Sun, Chuan-Yu, et al.
Publicado: (2022)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Current perspectives on bone metastases in castrate-resistant prostate cancer
por: Logothetis, Christopher, et al.
Publicado: (2018)

Leptomeningeal Metastases in a Patient with Castration-Resistant Prostate Cancer
por: Koie, Takuya, et al.
Publicado: (2020)

Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression
por: Ruchalski, Kathleen, et al.
Publicado: (2022)

Progression in immunotherapy for advanced prostate cancer
por: Liang, Hao, et al.
Publicado: (2023)

Cutaneous Metastases in Progressive Prostate Adenocarcinoma: A Case Report and Literature Review
por: Brito, Yesenia, et al.
Publicado: (2023)

Editorial: The role of STAT3 signaling pathway in tumor progression
por: Chang, Nan-Shan, et al.
Publicado: (2023)

TRIM66 promotes malignant progression of prostate carcinoma through the JAK/STAT pathway
por: Cao, Hongwen, et al.
Publicado: (2020)

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
por: Hegemann, Miriam, et al.
Publicado: (2019)

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases
por: Korpics, Mark C., et al.
Publicado: (2023)

Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells
por: Vakhrusheva, Olesya, et al.
Publicado: (2022)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cm8j2sjtub6ji2ofqe7175c295